# Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation

> **NCT07566585** · PHASE1 · RECRUITING · sponsor: **BlueSphere Bio, Inc** · enrollment: 19 (estimated)

## Conditions studied

- AML - Acute Myeloid Leukemia
- AML With Mutated NPM1
- AML, Adult Recurrent

## Interventions

- **DRUG:** SOC+ BSB-2002
- **DRUG:** SOC+BSB-2002

## Key facts

- **NCT ID:** NCT07566585
- **Lead sponsor:** BlueSphere Bio, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-21
- **Primary completion:** 2027-08
- **Final completion:** 2027-09
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07566585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07566585, "Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07566585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*